A股異動丨雙星新材(002585.SZ)封漲停 一季度淨利潤預增180%-200%
格隆匯3月12日丨雙星新材(002585.SZ)大幅高開,現已封死漲停板,報11.41元,買一封單超22萬後,最新總市值132億元。雙星新材昨日公佈,預計2021年一季度歸屬於上市公司股東的淨利潤2.46億元-2.63億元,同比增長180%-200%。公司圍繞服務國家發展大戰略,堅定推進戰略性新興產業新材料發展。五大板塊新材料通過不斷技術創新、產品開發,產銷持續增長,實現創新增效,光學材料、新能源材料領跑五大板塊。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.